Strongbridge Biopharma plc Announces Appointment of Jeffrey W. Sherman, M.D., FACP, to Board of Directors
October 03 2016 - 8:00AM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
biopharmaceutical company focused on the development and
commercialization of novel therapies for rare diseases, announced
today that Jeffrey W. Sherman, M.D., FACP, chief medical officer
and executive vice president of research and development at Horizon
Pharma plc, has been appointed to Strongbridge Biopharma’s Board of
Directors.
“Jeff’s extensive drug development experience,
along with his deep regulatory and business development expertise,
will be of tremendous value as we continue to grow Strongbridge and
drive the development of the Company’s rare disease portfolio,”
said Matthew Pauls, president, chief executive officer and member
of the Board of Directors of Strongbridge Biopharma plc.
“We are pleased to strengthen Strongbridge’s
depth and breadth of experience in the development and
commercialization of medications for the treatment of rare diseases
with the addition of Jeff to the Board of Directors,” said John H.
Johnson, chairman of the Board of Directors.
Dr. Sherman has more than 25 years of research,
clinical development, regulatory and commercialization experience
within the biopharmaceutical industry. Since 2009, he has served as
chief medical officer and an executive vice president at Horizon
Pharma. He also previously held senior leadership positions at IDM
Pharma, Takeda Global Research and Development, NeoPharm,
Searle/Pharmacia, Bristol-Myers Squibb, and is a past president of
the Drug Information Association (DIA). He earned his M.D. from the
Rosalind Franklin University of Medicine and Science/The Chicago
Medical School. He completed internship and residency programs at
Northwestern University Feinberg School of Medicine, where he
currently serves as an adjunct assistant professor, and a
fellowship position at the University of California San Francisco.
He received a B.A. in Biology from Lake Forest College.
“I am delighted to be joining Strongbridge’s
Board of Directors and look forward to leveraging my successful
track record in advancing novel therapeutics from clinical
development through commercial launch to help Strongbridge further
its efforts to bring new treatment options to the rare disease
community,” said Jeffrey W. Sherman, M.D., FACP.
About Strongbridge
Biopharma Strongbridge Biopharma is a global
biopharmaceutical company focused on the development and
commercialization of novel therapies for rare diseases.
Strongbridge’s lead product candidate, COR-003 (levoketoconazole),
is a cortisol inhibitor currently being studied in the global Phase
3 SONICS trial for the treatment of endogenous Cushing's syndrome.
Strongbridge’s rare endocrine disease franchise also includes
COR-005, a next-generation somatostatin analog (SSA) being
investigated for the treatment of acromegaly, with potential
additional applications in Cushing's syndrome and neuroendocrine
tumors. Both COR-003 and COR-005 have received orphan designation
from the U.S. Food and Drug Administration and
the European Medicines Agency. For more information,
visit www.strongbridgebio.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, contained in this press release, are
forward-looking statements. These statements relate to future
events and involve known and unknown risks, including, without
limitation, uncertainties regarding Strongbridge's strategy, plans
and objectives of management for future operations. The words
"anticipate," "estimate," "expect," "intend," "may," "plan,"
"potential," "project," "target," "will," "would," or the negative
of these terms or other similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections and are not guarantees of
future performance or development and involve known and unknown
risks, uncertainties and other factors. The forward-looking
statements contained in this press release are made as of the date
of this press release, and Strongbridge Biopharma does
not assume any obligation to update any forward-looking statements
except as required by applicable law.
Contacts:
Corporate and Media RelationsElixir Health
Public RelationsLindsay Rocco+1
862-596-1304lrocco@elixirhealthpr.com
Investor RelationsThe Trout GroupMarcy Nanus+1
646-378-2927mnanus@troutgroup.com
USA900 Northbrook DriveSuite 200Trevose, PA
19053Tel. +1 610-254-9200Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Sep 2023 to Sep 2024